dapsone has been researched along with Hemolysis in 65 studies
Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 9.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "Eighty patients with active rheumatoid arthritis (RA) entered a double-blind randomized study of 24 weeks duration, to compare the efficacy and toxicity of hydroxychloroquine, dapsone, and a combination of both drugs in treatment of RA." | 9.07 | A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. ( Christensen, L; Haar, D; Hansen, TM; Rasmussen, KJ; Sølvkjaer, M; Unger, B, 1993) |
| "This case highlights the potential for therapeutic levels of dapsone to induce side effects in patients without G6PD deficiency and highlights the importance of routine blood monitoring for anemia and hemolysis during the course of drug therapy." | 8.12 | Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria. ( Awan, M; Brown, LE; Gandelman, JS; Geere, M; Hu, Y; Kogan, SC; Leavitt, AD; Pearson, HJ, 2022) |
| "Dapsone hydroxylamine (DDS-NHOH), N-hydroxylated metabolite of a sulfonamide antibiotic, dapsone, is responsible for various adverse effects of dapsone that include methemoglobinemia, hemolytic anemia, and thrombosis." | 7.91 | Dapsone Hydroxylamine, an Active Metabolite of Dapsone, Can Promote the Procoagulant Activity of Red Blood Cells and Thrombosis. ( An, GJ; Bae, ON; Bian, Y; Chung, JH; Kim, K; Lim, KM; Ngo, T, 2019) |
| " She was chronically treated with dapsone (50 mg/day) for a dermatologic disease and denied any drug overdose." | 7.81 | Acute visual loss following dapsone-induced methemoglobinemia and hemolysis. ( Hantson, P; Hanuschk, D; Kozyreff, A; Saint-Marcoux, F; Tafzi, N; Tennstedt, D, 2015) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 7.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "Dapsone (4,4'diaminodiphenyl-sulphone) commonly used in the treatment of patients who suffer from leprosy, is a strongly oxidative drug, producing damage to the red cell membrane." | 7.69 | [Vitamin E as protective agent against hemolysis in leprosy patients under dapsone treatment]. ( Artaza, JR; Carbia, CD; Díaz, NB; Lardo, MM; Nazer, R; Valdez, R, 1997) |
| "This study looked at whether oral vitamin C and vitamin E would protect the erythrocyte from oxidant damage caused by dapsone in patients with dermatitis herpetiformis." | 7.68 | The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. ( Ali, MA; Guyatt, G; Prussick, R; Rosenthal, D, 1992) |
| "Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized." | 7.68 | Effect of dapsone on haemoglobin concentration in patients with leprosy. ( Byrd, SR; Gelber, RH, 1991) |
| "Sixteen patients, each receiving 100 mg of dapsone per day, were studied for evidence of hemolysis." | 7.67 | Vitamin E and dapsone-induced hemolysis. ( Kelly, JW; Marks, R; Sandland, M; Scott, J; Van der Weyden, MB, 1984) |
| "Fifty one patients with leprosy from the Urban Leprosy Centre, attached to the Department of Dermatology and Venereology, Goa Medical College on treatment with Dapsone were studied from the point of view of development of haemolysis related to the drug." | 7.66 | Dapsone haemolysis in leprosy. A preliminary report. ( Menezes, S; Rege, VL; Sehgal, VN, 1981) |
| "Dapsone has been used in various dermatological disorders and in leprosy." | 7.66 | Dapsone induced hypohaptoglobinemia in lepromatous leprosy patients. ( Bharadwaj, VP; Girdhar, BK; Sritharan, V; Venkatesan, K, 1981) |
| "Methemoglobinemia and hemolysis are well-known side effects after using high doses of dapsone (4,4'-diaminodiphenylsulfone)." | 7.66 | Dapsone-induced methemoglobinemia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemoglobin reductase deficiency. ( Fryd, CH; Ganer, A; Knobel, B; Rachmilewitz, EA, 1981) |
| "Dapsone is a highly useful drug for treating a variety of pathologies but oral dapsone is contraindicated in patients with G6PDd due to oxidative stress-induced anemia." | 5.91 | Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model. ( D'Alessandro, A; Dziewulska, KH; Hay, AM; Reisz, JA; Zimring, JC, 2023) |
| "Oxidant hemolysis is a known complication of dapsone, but its frequency in adult patients who have undergone a SCT for hematological malignancies is not well established." | 5.38 | High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. ( Bredeson, C; George, B; Hari, PN; Harrington, AM; Kroft, SH; Olteanu, H, 2012) |
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 5.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "Eighty patients with active rheumatoid arthritis (RA) entered a double-blind randomized study of 24 weeks duration, to compare the efficacy and toxicity of hydroxychloroquine, dapsone, and a combination of both drugs in treatment of RA." | 5.07 | A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. ( Christensen, L; Haar, D; Hansen, TM; Rasmussen, KJ; Sølvkjaer, M; Unger, B, 1993) |
| "This case highlights the potential for therapeutic levels of dapsone to induce side effects in patients without G6PD deficiency and highlights the importance of routine blood monitoring for anemia and hemolysis during the course of drug therapy." | 4.12 | Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria. ( Awan, M; Brown, LE; Gandelman, JS; Geere, M; Hu, Y; Kogan, SC; Leavitt, AD; Pearson, HJ, 2022) |
| "Dapsone hydroxylamine (DDS-NHOH), N-hydroxylated metabolite of a sulfonamide antibiotic, dapsone, is responsible for various adverse effects of dapsone that include methemoglobinemia, hemolytic anemia, and thrombosis." | 3.91 | Dapsone Hydroxylamine, an Active Metabolite of Dapsone, Can Promote the Procoagulant Activity of Red Blood Cells and Thrombosis. ( An, GJ; Bae, ON; Bian, Y; Chung, JH; Kim, K; Lim, KM; Ngo, T, 2019) |
| " She was chronically treated with dapsone (50 mg/day) for a dermatologic disease and denied any drug overdose." | 3.81 | Acute visual loss following dapsone-induced methemoglobinemia and hemolysis. ( Hantson, P; Hanuschk, D; Kozyreff, A; Saint-Marcoux, F; Tafzi, N; Tennstedt, D, 2015) |
| " A 50-year-old male with well-controlled type 1 DM, Mb Addison and coeliac disease was diagnosed with dermatitis herpetiformis and treated with dapsone." | 3.79 | [Dapsone-induced decrease in the HbA(1c) level may cause artefacts in diabetic control]. ( Hermansen, K; Ladefoged, SA; Lajlev, SE, 2013) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 3.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "Dapsone (4,4'diaminodiphenyl-sulphone) commonly used in the treatment of patients who suffer from leprosy, is a strongly oxidative drug, producing damage to the red cell membrane." | 3.69 | [Vitamin E as protective agent against hemolysis in leprosy patients under dapsone treatment]. ( Artaza, JR; Carbia, CD; Díaz, NB; Lardo, MM; Nazer, R; Valdez, R, 1997) |
| "This study looked at whether oral vitamin C and vitamin E would protect the erythrocyte from oxidant damage caused by dapsone in patients with dermatitis herpetiformis." | 3.68 | The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. ( Ali, MA; Guyatt, G; Prussick, R; Rosenthal, D, 1992) |
| "Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized." | 3.68 | Effect of dapsone on haemoglobin concentration in patients with leprosy. ( Byrd, SR; Gelber, RH, 1991) |
| "Sixteen patients, each receiving 100 mg of dapsone per day, were studied for evidence of hemolysis." | 3.67 | Vitamin E and dapsone-induced hemolysis. ( Kelly, JW; Marks, R; Sandland, M; Scott, J; Van der Weyden, MB, 1984) |
| "Methemoglobinemia and hemolysis are well-known side effects after using high doses of dapsone (4,4'-diaminodiphenylsulfone)." | 3.66 | Dapsone-induced methemoglobinemia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemoglobin reductase deficiency. ( Fryd, CH; Ganer, A; Knobel, B; Rachmilewitz, EA, 1981) |
| "Dapsone has been used in various dermatological disorders and in leprosy." | 3.66 | Dapsone induced hypohaptoglobinemia in lepromatous leprosy patients. ( Bharadwaj, VP; Girdhar, BK; Sritharan, V; Venkatesan, K, 1981) |
| "Fifty one patients with leprosy from the Urban Leprosy Centre, attached to the Department of Dermatology and Venereology, Goa Medical College on treatment with Dapsone were studied from the point of view of development of haemolysis related to the drug." | 3.66 | Dapsone haemolysis in leprosy. A preliminary report. ( Menezes, S; Rege, VL; Sehgal, VN, 1981) |
| "Dapsone is a highly useful drug for treating a variety of pathologies but oral dapsone is contraindicated in patients with G6PDd due to oxidative stress-induced anemia." | 1.91 | Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model. ( D'Alessandro, A; Dziewulska, KH; Hay, AM; Reisz, JA; Zimring, JC, 2023) |
| "Dapsone has been the mainstay for the treatment of leprosy since its discovery in the 1940s." | 1.56 | Hematological alterations in lepromatous leprosy: A cross-sectional observational study. ( Awan, KH; Chaudhary, M; Gupta, B; Gupta, S; Patil, S; Raj, AT, 2020) |
| "Dapsone may be used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in hematology patients receiving immunosuppressive therapy or after hematopoietic stem cell transplant (HSCT) in the setting of trimethoprim-sulfamethoxazole (TMP-SMX) adverse drug reaction (ADR) history." | 1.48 | Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. ( Pisasale, D; Trubiano, JA; Urbancic, KF; Wight, J, 2018) |
| "Oxidant hemolysis is a known complication of dapsone, but its frequency in adult patients who have undergone a SCT for hematological malignancies is not well established." | 1.38 | High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. ( Bredeson, C; George, B; Hari, PN; Harrington, AM; Kroft, SH; Olteanu, H, 2012) |
| "Epiandrosterone was found to inhibit rat red cell G6PD uncompetitively and to suppress red cell hexose monophosphate shunt activity by more than 95%." | 1.29 | Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. ( Budinsky, R; Grossman, S; Jollow, D, 1995) |
| " It is suggested that dapsone dosage be regulated to body weight and preferably not to exceed 1." | 1.28 | Investigations into the haemolytic effects of dapsone therapy in leprosy patients. ( Balakrishnan, S; Karthikeyan, S; Ramu, G, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (46.15) | 18.7374 |
| 1990's | 13 (20.00) | 18.2507 |
| 2000's | 5 (7.69) | 29.6817 |
| 2010's | 11 (16.92) | 24.3611 |
| 2020's | 6 (9.23) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y | 3 |
| Geere, M | 3 |
| Awan, M | 3 |
| Leavitt, AD | 3 |
| Brown, LE | 3 |
| Pearson, HJ | 3 |
| Gandelman, JS | 3 |
| Kogan, SC | 3 |
| Dziewulska, KH | 1 |
| Reisz, JA | 1 |
| Hay, AM | 1 |
| D'Alessandro, A | 1 |
| Zimring, JC | 1 |
| Bian, Y | 1 |
| Kim, K | 1 |
| An, GJ | 1 |
| Ngo, T | 1 |
| Bae, ON | 1 |
| Lim, KM | 1 |
| Chung, JH | 1 |
| Ezhilarasan, D | 1 |
| Gupta, B | 1 |
| Gupta, S | 1 |
| Chaudhary, M | 1 |
| Raj, AT | 1 |
| Awan, KH | 1 |
| Patil, S | 1 |
| Gallardo, CA | 1 |
| Fan, BE | 1 |
| Lim, KGE | 1 |
| Kuperan, P | 1 |
| Gul, J | 1 |
| Ullah, S | 1 |
| Ali, I | 1 |
| Rao, K | 1 |
| Iqbal, KM | 1 |
| Jabri, T | 1 |
| Perveen, S | 1 |
| Rashid, A | 1 |
| Shah, MR | 1 |
| Corallo, C | 1 |
| Coutsouvelis, J | 1 |
| Avery, S | 1 |
| Morgan, S | 1 |
| Morrissey, O | 1 |
| Urbancic, KF | 1 |
| Pisasale, D | 1 |
| Wight, J | 1 |
| Trubiano, JA | 1 |
| Lajlev, SE | 1 |
| Ladefoged, SA | 1 |
| Hermansen, K | 1 |
| Luzzatto, L | 1 |
| Seneca, E | 1 |
| Hanuschk, D | 1 |
| Kozyreff, A | 1 |
| Tafzi, N | 1 |
| Tennstedt, D | 1 |
| Hantson, P | 1 |
| Saint-Marcoux, F | 1 |
| Poirot, E | 1 |
| Vittinghoff, E | 1 |
| Ishengoma, D | 1 |
| Alifrangis, M | 1 |
| Carneiro, I | 1 |
| Hashim, R | 1 |
| Baraka, V | 1 |
| Mosha, J | 1 |
| Gesase, S | 1 |
| Chandramohan, D | 1 |
| Gosling, R | 1 |
| Flosadóttir, E | 1 |
| Bjarnason, B | 1 |
| Tiono, AB | 1 |
| Dicko, A | 1 |
| Ndububa, DA | 1 |
| Agbenyega, T | 1 |
| Pitmang, S | 1 |
| Awobusuyi, J | 1 |
| Pamba, A | 1 |
| Duparc, S | 1 |
| Goh, LE | 1 |
| Harrell, E | 1 |
| Carter, N | 1 |
| Ward, SA | 1 |
| Greenwood, B | 1 |
| Winstanley, PA | 1 |
| Pallais, JC | 1 |
| Mackool, BT | 1 |
| Pitman, MB | 1 |
| Olteanu, H | 1 |
| Harrington, AM | 1 |
| George, B | 1 |
| Hari, PN | 1 |
| Bredeson, C | 1 |
| Kroft, SH | 1 |
| Hsia, CC | 1 |
| Chin-Yee, IH | 1 |
| Deps, P | 1 |
| Guerra, P | 1 |
| Nasser, S | 1 |
| Simon, M | 1 |
| Serratrice, J | 1 |
| Granel, B | 1 |
| Swiader, L | 1 |
| Disdier, P | 1 |
| De Roux-Serratrice, C | 1 |
| Raccah, D | 1 |
| Weiller, PJ | 1 |
| PENGELLY, CD | 1 |
| McMillan, DC | 2 |
| Powell, CL | 1 |
| Bowman, ZS | 1 |
| Morrow, JD | 1 |
| Jollow, DJ | 2 |
| Chalioulias, K | 1 |
| Mayer, E | 1 |
| Darvay, A | 1 |
| Antcliff, R | 1 |
| Endre, ZH | 1 |
| Charlesworth, JA | 1 |
| Macdonald, GJ | 1 |
| Woodbridge, L | 1 |
| Revuz, J | 1 |
| Hornac, P | 1 |
| Kelly, JW | 1 |
| Scott, J | 1 |
| Sandland, M | 1 |
| Van der Weyden, MB | 1 |
| Marks, R | 1 |
| Ganer, A | 1 |
| Knobel, B | 1 |
| Fryd, CH | 1 |
| Rachmilewitz, EA | 1 |
| Sritharan, V | 1 |
| Bharadwaj, VP | 1 |
| Venkatesan, K | 1 |
| Girdhar, BK | 1 |
| Menezes, S | 1 |
| Rege, VL | 1 |
| Sehgal, VN | 2 |
| Magon, AM | 1 |
| Leipzig, RM | 2 |
| Zannoni, VG | 1 |
| Brewer, GJ | 2 |
| Magon, A | 1 |
| Bloom, K | 1 |
| Grossman, S | 1 |
| Budinsky, R | 1 |
| Jollow, D | 1 |
| Rhodes, LE | 1 |
| Tingle, MD | 1 |
| Park, BK | 1 |
| Chu, P | 1 |
| Verbov, JL | 1 |
| Friedmann, PS | 1 |
| Smith, KC | 1 |
| Haar, D | 1 |
| Sølvkjaer, M | 1 |
| Unger, B | 1 |
| Rasmussen, KJ | 1 |
| Christensen, L | 1 |
| Hansen, TM | 1 |
| Chatterjee, N | 1 |
| Mehta, VL | 1 |
| Tayal, G | 1 |
| Bradshaw, TP | 1 |
| Crouch, RK | 1 |
| Lardo, MM | 1 |
| Díaz, NB | 1 |
| Artaza, JR | 1 |
| Carbia, CD | 1 |
| Nazer, R | 1 |
| Valdez, R | 1 |
| Southgate, HJ | 1 |
| Masterson, R | 1 |
| Ciccoli, L | 1 |
| Ferrali, M | 1 |
| Rossi, V | 1 |
| Signorini, C | 1 |
| Alessandrini, C | 1 |
| Comporti, M | 1 |
| Elonen, E | 1 |
| Neuvonen, PJ | 1 |
| Halmekoski, J | 2 |
| Mattila, MJ | 3 |
| Kesson, CM | 1 |
| Whitelaw, JW | 1 |
| Ireland, JT | 1 |
| Lang, PG | 1 |
| Poshyachinda, M | 1 |
| Buachum, V | 1 |
| Mahasandana, S | 1 |
| Mustakallio, KK | 2 |
| Wilson, JR | 1 |
| Harris, JW | 1 |
| Kashyap, A | 1 |
| Saha, K | 1 |
| Prussick, R | 1 |
| Ali, MA | 1 |
| Rosenthal, D | 1 |
| Guyatt, G | 1 |
| Byrd, SR | 1 |
| Gelber, RH | 1 |
| Balakrishnan, S | 1 |
| Karthikeyan, S | 1 |
| Ramu, G | 1 |
| Hjelm, M | 1 |
| de Verdier, CH | 1 |
| Carson, PE | 4 |
| Förström, L | 1 |
| Cucinell, SA | 1 |
| Rebert, C | 1 |
| Clyde, D | 1 |
| Glader, BE | 1 |
| Conrad, ME | 1 |
| Rasbridge, MR | 3 |
| Scott, GL | 4 |
| DeGowin, RL | 3 |
| McNamara, JV | 2 |
| Eppes, RB | 3 |
| Powell, RD | 3 |
| Gaetani, G | 1 |
| Salvidio, E | 1 |
| Pannacciulli, I | 1 |
| Ajmar, F | 1 |
| Paravidino, G | 1 |
| Cream, JJ | 1 |
5 reviews available for dapsone and Hemolysis
| Article | Year |
|---|---|
Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia.
Topics: Animals; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Dapsone; Dose-Response Relat | 2021 |
Dapsone and azole interactions: A clinical perspective.
Topics: Anti-Infective Agents; Azoles; Dapsone; Drug Interactions; Hemolysis; Humans | 2018 |
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.
Topics: Anemia, Hemolytic; Animals; Antimalarials; Dapsone; Female; Glucosephosphate Dehydrogenase Deficienc | 2014 |
[Side effects of treatment with sulfones].
Topics: Adult; Agranulocytosis; Chemical and Drug Induced Liver Injury; Child; Dapsone; Drug Eruptions; Drug | 1981 |
A review of therapeutic and hemolytic effects of dapsone.
Topics: Dapsone; Hemolysis; Humans | 1967 |
3 trials available for dapsone and Hemolysis
57 other studies available for dapsone and Hemolysis
| Article | Year |
|---|---|
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Dapsone-induced methemoglobinemia and hemolysis in a woman without G6PD deficiency presenting with idiopathic urticaria.
Topics: Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Methemoglobinemia; Ur | 2022 |
Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model.
Topics: Animals; Dapsone; Erythrocytes; Glucose; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Human | 2023 |
Dapsone Hydroxylamine, an Active Metabolite of Dapsone, Can Promote the Procoagulant Activity of Red Blood Cells and Thrombosis.
Topics: Adult; Animals; Blood Coagulation; Cells, Cultured; Dapsone; Dose-Response Relationship, Drug; Eryth | 2019 |
Hematological alterations in lepromatous leprosy: A cross-sectional observational study.
Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Dapsone; Erythrocyte Indices; Female; Hematocr | 2020 |
Chronic dapsone use causing methemoglobinemia with oxidative hemolysis and dyserythropoiesis.
Topics: Aged, 80 and over; Anti-Infective Agents; Dapsone; Erythrocytes; Erythropoiesis; Female; Folic Acid | 2021 |
Synthesis, characterization and drug delivery application of Dapsone based double tailed biocompatible nonionic surfactant.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Biofilms; Dapsone; Drug Carriers; Drug Liberation; G | 2021 |
Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Topics: Aged; Anemia, Hemolytic; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Hematologic | 2018 |
[Dapsone-induced decrease in the HbA(1c) level may cause artefacts in diabetic control].
Topics: Anti-Infective Agents; Dapsone; Dermatitis Herpetiformis; Diabetes Mellitus, Type 1; Glycated Hemogl | 2013 |
Acute visual loss following dapsone-induced methemoglobinemia and hemolysis.
Topics: Acute Disease; Adult; Dapsone; Drug Overdose; Female; Hemolysis; Humans; Ischemia; Methemoglobinemia | 2015 |
Full dapsone dose made possible by control of anaemia with darbepoetin-alpha.
Topics: Aged, 80 and over; Anemia, Hemolytic; Dapsone; Darbepoetin alfa; Dose-Response Relationship, Drug; E | 2008 |
Case records of the Massachusetts General Hospital: Case 7-2011: a 52-year-old man with upper respiratory symptoms and low oxygen saturation levels.
Topics: Celiac Disease; Cough; Dapsone; Dermatitis Herpetiformis; Diabetes Mellitus, Type 1; Diagnosis, Diff | 2011 |
High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency.
Topics: Adult; Anti-Infective Agents; Dapsone; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehy | 2012 |
Dapsone hemolysis.
Topics: Aged; Anti-Infective Agents; Dapsone; Erythrocytes; Female; Hemolysis; Humans; Lichen Planus | 2012 |
Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Brazil; Clofazimine; Dapsone; Drug Therapy, Combination; | 2012 |
Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Blood Gluco | 2002 |
DAPSONE-INDUCED HAEMOLYSIS.
Topics: Chromium Isotopes; Dapsone; Dermatitis Herpetiformis; Hemolysis; Humans; Sulfones; Toxicology | 1963 |
Lipids versus proteins as major targets of pro-oxidant, direct-acting hemolytic agents.
Topics: Animals; Dapsone; Dose-Response Relationship, Drug; Erythrocytes; Hemoglobins; Hemolysis; Humans; In | 2005 |
Anterior ischaemic optic neuropathy associated with Dapsone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Dermatitis Herpetiformis; Diabetes Mellitus, Type | 2006 |
Successful treatment of acute dapsone intoxication using charcoal hemoperfusion.
Topics: Acne Vulgaris; Adult; Charcoal; Dapsone; Female; Hemolysis; Hemoperfusion; Humans; Hypoxia; Methemog | 1983 |
Vitamin E and dapsone-induced hemolysis.
Topics: Adult; Aged; Dapsone; Dermatitis Herpetiformis; Erythrocyte Count; Female; Heinz Bodies; Hemoglobins | 1984 |
Dapsone-induced methemoglobinemia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemoglobin reductase deficiency.
Topics: Adult; Cytochrome-B(5) Reductase; Dapsone; Hemoglobinopathies; Hemoglobins, Abnormal; Hemolysis; Hum | 1981 |
Dapsone induced hypohaptoglobinemia in lepromatous leprosy patients.
Topics: Adult; Alkaline Phosphatase; Dapsone; Haptoglobins; Hemoglobins; Hemolysis; Humans; L-Lactate Dehydr | 1981 |
Dapsone haemolysis in leprosy. A preliminary report.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Bilirubin; Child; Dapsone; Female; Hemolysis; Humans; Le | 1981 |
Interactions of glucose-6-phosphate dehydrogenase deficiency with drug acetylation and hydroxylation reactions.
Topics: Acetylation; Animals; Dapsone; Erythrocytes; Glucosephosphate Dehydrogenase Deficiency; Glutathione; | 1981 |
Pharmacogenetic interactions in G6PD deficiency and development of an in vitro test to predict a drug's hemolytic potential.
Topics: Animals; Dapsone; Drug Evaluation, Preclinical; Erythrocytes; Glucosephosphate Dehydrogenase Deficie | 1981 |
Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.
Topics: Amitrole; Androsterone; Anemia, Hemolytic; Animals; Dapsone; Erythrocytes; Glucosephosphate Dehydrog | 1995 |
Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy.
Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Dapsone; Dermatitis Herpetiformis; Drug Therapy, Combina | 1995 |
Vitamin E and dapsone-induced hemolysis.
Topics: Dapsone; Hemolysis; Humans; Vitamin E | 1994 |
Protective effect of fluoroquinolones on dapsone induced erythrolysis.
Topics: Animals; Dapsone; Hemolysis; In Vitro Techniques; Osmotic Fragility; Quinolones; Rabbits | 1995 |
Formation of free radicals and protein mixed disulfides in rat red cells exposed to dapsone hydroxylamine.
Topics: Animals; Cyclic N-Oxides; Cysteamine; Dapsone; Disulfides; Electron Spin Resonance Spectroscopy; Ery | 1997 |
[Vitamin E as protective agent against hemolysis in leprosy patients under dapsone treatment].
Topics: Adult; Dapsone; Female; Hemolysis; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Vitamin E | 1997 |
Lessons to be learned: a case study approach: prolonged methaemoglobinaemia due to inadvertent dapsone poisoning; treatment with methylene blue and exchange transfusion.
Topics: Adult; Antidotes; Baclofen; Dapsone; Exchange Transfusion, Whole Blood; Folic Acid Antagonists; Hemo | 1999 |
Hemolytic drugs aniline and dapsone induce iron release in erythrocytes and increase the free iron pool in spleen and liver.
Topics: Aniline Compounds; Animals; Dapsone; Erythrocytes; Hemolysis; Hydroxylamines; Iron; Leprostatic Agen | 1999 |
Acute dapsone intoxication: a case with prolonged symptoms.
Topics: Acetylation; Biotransformation; Dapsone; Hemolysis; Humans; Male; Methemoglobinemia; Middle Aged; Ti | 1979 |
Drug-induced haemolysis and fast haemoglobin A1 in diabetes mellitus.
Topics: Dapsone; Diabetes Mellitus; Hemoglobin A; Hemolysis; Humans; Male; Middle Aged | 1979 |
Sulfones and sulfonamides in dermatology today.
Topics: Agranulocytosis; Dapsone; Drug Hypersensitivity; Hemolysis; Humans; Kidney Diseases; Methemoglobinem | 1979 |
Haemolytic side effects of DFD in normal and G-6-PD deficient Thais.
Topics: Adult; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Middle Aged; Thailand | 1978 |
Metabolism and haemolytic effect of dapsone and its metabolites in man.
Topics: Acetylation; Administration, Oral; Chemical Phenomena; Chemistry; Chromatography, Thin Layer; Dapson | 1978 |
Hematologic side-effects of dapsone.
Topics: Adult; Agranulocytosis; Dapsone; Female; Hematologic Diseases; Hematopoietic System; Hemolysis; Huma | 1977 |
Reconstruction of anti-leprosy drug depleted complement haemolytic activity by addition of zymosan-treated sera (a source of C142) and CratEDTA (a source of C3-C9).
Topics: Animals; Chloroquine; Clofazimine; Complement Activation; Complement System Proteins; Dapsone; Edeti | 1992 |
The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis.
Topics: Adult; Ascorbic Acid; Blood Cell Count; Dapsone; Dermatitis Herpetiformis; Female; Heinz Bodies; Hem | 1992 |
Glucose-6-phosphate dehydrogenase deficiency.
Topics: Acetaminophen; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans | 1991 |
Effect of dapsone on haemoglobin concentration in patients with leprosy.
Topics: Adolescent; Adult; Aged; Child; Dapsone; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglob | 1991 |
Investigations into the haemolytic effects of dapsone therapy in leprosy patients.
Topics: Adolescent; Adult; Bilirubin; Body Weight; Child; Dapsone; Drug Administration Schedule; Erythrocyte | 1989 |
Biochemical effects of aromatic amines. I. Methaemoglobinaemia, haemolysis and Heinz-body formation induced by 4,4'-diaminodiphenylsulphone.
Topics: Chromatography, Ion Exchange; Cytoplasm; Dapsone; Dermatitis Herpetiformis; Erythrocytes; Heinz Bodi | 1965 |
Hemolysis due to inherited erythrocyte enzyme deficiencies.
Topics: Age Factors; Asia, Southeastern; Dapsone; Erythrocytes; Genetics, Population; Glucose; Glucosephosph | 1968 |
Acetylator phenotype, minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis.
Topics: Acetylation; Adult; Aged; Dapsone; Dermatitis Herpetiformis; Dose-Response Relationship, Drug; Femal | 1974 |
Clinical pharmacology of diformyldapsone.
Topics: Chloroquine; Dapsone; Drug Therapy, Combination; Erythrocytes; Formaldehyde; Glucosephosphate Dehydr | 1974 |
Hemolysis by diphenylsulfones: comparative effects of DDS and hydroxylamine-DDS.
Topics: Amitrole; Animals; Ascorbic Acid; Catalase; Cell Survival; Chromium Isotopes; Dapsone; Erythrocytes; | 1973 |
The haemolytic action of dapsone: the effect on red-cell glycolysis.
Topics: Adenosine Triphosphate; Adult; Aged; Dapsone; Dermatitis Herpetiformis; Erythrocyte Aging; Erythrocy | 1973 |
The haemolytic action of dapsone: changes in the red-cell membrane.
Topics: Acetylcholinesterase; Adult; Aged; Catalase; Cell Membrane; Chloromercuribenzoates; Cysteine; Dapson | 1973 |
The in vitro action of dapsone and its derivatives on normal and G6PD-deficient red cells.
Topics: Acetylcholinesterase; Adenosine Triphosphate; Cell Membrane; Dapsone; Erythrocytes; Glucose; Glucose | 1973 |
The effects of para-aminobenzoic acid on the hemolytic effects of 4, 4'-diaminodiphenylsulfone.
Topics: Adult; Aminobenzoates; Black or African American; Dapsone; Glucosephosphate Dehydrogenase Deficiency | 1966 |
Chloroquine-resistant Plasmodium falciparum: protective and hemolytic effects of 4,4'-diaminodiphenylsulfone (DDS) administered daily together with weekly chloroquine and primaquine.
Topics: Adult; Black or African American; Chloroquine; Dapsone; Hemolysis; Humans; Malaria; Male; Plasmodium | 1967 |
The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency.
Topics: Adult; Black or African American; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Hum | 1966 |
Absence of hemolytic effects of L-DOPA on transfused G6PD-deficient erythrocytes.
Topics: Blood Transfusion; Chromium Isotopes; Dapsone; Dihydroxyphenylalanine; Erythrocytes; Favism; Female; | 1970 |
Anaemia in dermatitis herpetiformis. The role of dapsone-induced haemolysis and malabsorption.
Topics: Adult; Aged; Anemia, Hemolytic; Anemia, Hypochromic; Anemia, Pernicious; Dapsone; Dermatitis Herpeti | 1970 |